Bristol-Myers Squibb Company (BMY): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Bristol-Myers Squibb Company ( BMY) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.0%. By the end of trading, Bristol-Myers Squibb Company fell $0.56 (-1.1%) to $52.85 on average volume. Throughout the day, 5,821,480 shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 7,250,100 shares. The stock ranged in price between $52.72-$53.61 after having opened the day at $53.39 as compared to the previous trading day's close of $53.41. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 38.6%, Bacterin International Holdings ( BONE), down 15.9%, Merus Labs International ( MSLI), down 10.4% and Agios Pharmaceuticals ( AGIO), down 10.0%.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $86.2 billion and is part of the health care sector. The company has a P/E ratio of 31.5, above the S&P 500 P/E ratio of 17.7. Shares are up 60.6% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, solid stock price performance, impressive record of earnings per share growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the positive front, Prima Biomed ( PBMD), up 38.9%, Ariad Pharmaceuticals ( ARIA), up 35.7%, ImmunoCellular Therapeutics ( IMUC), up 35.7% and IntelliPharmaCeutics International ( IPCI), up 19.0% , were all gainers within the drugs industry with Biogen Idec ( BIIB) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Stocks Trade Mixed, Energy Shares Fall on Sharp Drop in Oil Prices

Stocks Trade Mixed, Energy Shares Fall on Sharp Drop in Oil Prices

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Component Stocks Rise After Trump Reverses Decision on ZTE

Component Stocks Rise After Trump Reverses Decision on ZTE

Crude Slides as Russia Eases Cuts and U.S. Oil Producers Boost Rig Count

Crude Slides as Russia Eases Cuts and U.S. Oil Producers Boost Rig Count

Best Buy's Billionaire Founder: We Were 'Late to the Game' in Online Shopping

Best Buy's Billionaire Founder: We Were 'Late to the Game' in Online Shopping